当代医学
噹代醫學
당대의학
CHINA CONTEMPORARY MEDICINE
2013年
22期
5-6
,共2页
非酒精性脂肪肝%还原型谷胱甘肽%左卡尼汀%肝功能%血脂
非酒精性脂肪肝%還原型穀胱甘肽%左卡尼汀%肝功能%血脂
비주정성지방간%환원형곡광감태%좌잡니정%간공능%혈지
Nonalcoholic fatty liver%Glutathione%L-carnitine%Liver function%Blood lipid
目的探讨非酒精性脂肪肝联合应用还原型谷胱甘肽、左卡尼汀治疗前后患者肝功能及血脂变化情况。方法选取60例非酒精性脂肪肝患者，随机分为观察组和对照组，各30例。观察组在常规治疗基础上联合应用还原型谷胱甘肽1.2 g、左卡尼汀3.0 g，1次/d,对照组在常规治疗基础上单纯应用还原型谷胱甘肽1.2 g，1次/d；均连续治疗14 d，比较两组治疗前后肝功能及血脂水平改善情况。结果两组治疗14 d后，肝功能ALT、AST指标较治疗前均明显降低，差异有统计学意义（均P<0.05）；两组治疗后血脂水平较治疗前均下降：观察组治疗14 d后血清TG为1.34 mmol/L、TC 4.56 mmol/L，治疗前TG 3.28 mmol/L、TC 8.01 mmol/L，前后差异明显，且有统计学意义（P均<0.05），而对照组治疗14 d后血清TG 2.11 mmol/L、TC 4.98 mmol/L，治疗前血清TG 3.09 mmol/L、TC 97.23 mmol/L，治疗前后下降不明显，差异无统计学意义（P均>0.05）。结论还原型谷胱甘肽联合左卡尼汀治疗非酒精性脂肪肝可较好改善肝功能和血脂水平，值得临床推广和应用。
目的探討非酒精性脂肪肝聯閤應用還原型穀胱甘肽、左卡尼汀治療前後患者肝功能及血脂變化情況。方法選取60例非酒精性脂肪肝患者，隨機分為觀察組和對照組，各30例。觀察組在常規治療基礎上聯閤應用還原型穀胱甘肽1.2 g、左卡尼汀3.0 g，1次/d,對照組在常規治療基礎上單純應用還原型穀胱甘肽1.2 g，1次/d；均連續治療14 d，比較兩組治療前後肝功能及血脂水平改善情況。結果兩組治療14 d後，肝功能ALT、AST指標較治療前均明顯降低，差異有統計學意義（均P<0.05）；兩組治療後血脂水平較治療前均下降：觀察組治療14 d後血清TG為1.34 mmol/L、TC 4.56 mmol/L，治療前TG 3.28 mmol/L、TC 8.01 mmol/L，前後差異明顯，且有統計學意義（P均<0.05），而對照組治療14 d後血清TG 2.11 mmol/L、TC 4.98 mmol/L，治療前血清TG 3.09 mmol/L、TC 97.23 mmol/L，治療前後下降不明顯，差異無統計學意義（P均>0.05）。結論還原型穀胱甘肽聯閤左卡尼汀治療非酒精性脂肪肝可較好改善肝功能和血脂水平，值得臨床推廣和應用。
목적탐토비주정성지방간연합응용환원형곡광감태、좌잡니정치료전후환자간공능급혈지변화정황。방법선취60례비주정성지방간환자，수궤분위관찰조화대조조，각30례。관찰조재상규치료기출상연합응용환원형곡광감태1.2 g、좌잡니정3.0 g，1차/d,대조조재상규치료기출상단순응용환원형곡광감태1.2 g，1차/d；균련속치료14 d，비교량조치료전후간공능급혈지수평개선정황。결과량조치료14 d후，간공능ALT、AST지표교치료전균명현강저，차이유통계학의의（균P<0.05）；량조치료후혈지수평교치료전균하강：관찰조치료14 d후혈청TG위1.34 mmol/L、TC 4.56 mmol/L，치료전TG 3.28 mmol/L、TC 8.01 mmol/L，전후차이명현，차유통계학의의（P균<0.05），이대조조치료14 d후혈청TG 2.11 mmol/L、TC 4.98 mmol/L，치료전혈청TG 3.09 mmol/L、TC 97.23 mmol/L，치료전후하강불명현，차이무통계학의의（P균>0.05）。결론환원형곡광감태연합좌잡니정치료비주정성지방간가교호개선간공능화혈지수평，치득림상추엄화응용。
Objective To explore the combined application of nonalcoholic fatty liver was also reduced glutathione, before and after L-carnitine treatment function and the changes of blood lipid in patients with liver disease. Methods 60 patients with nonalcoholic fatty liver patients, randomly divided into observation group and control group, each of 30 cases,. The observation group in the conventional treatment based on the combined application of glutathione 1.2 g, L-carnitine 3.0 g, 1/d, the control group in the conventional treatment on the basis of the simple application of the glutathione 1.2 g, 1 times/d;treated continuously for 14 d, compared two groups before and after treatment of hepatic function and blood lipid level to improve the situation. Results Of the two groups after the treatment of 14 d, ALT, AST and liver function parameters were signiifcantly lower than that before treatment, the difference was statistically signiifcant (all P<0.05);the two group after treatment than before treatment decreased lipid levels: the observation group after treatment for 14 d serum TG was 1.34 mmol/L, TC 4.56 mmol/L, TG 3.28 mmol/L, TC 8.01 mmol/L before and after treatment, signiifcant difference, and there was statistical signiifcance (P<0.05), while the control group 14 d after treatment, serum TG 2.11 mmol/L TC 4.98 mmol/L, serum TG, TC 97.23 mmol/L and 3.09 mmol/L before treatment, after treatment decreased signiifcantly, no signiifcant difference (P>0.05). Conclusion Glutathione combined with Levocarnitine in the treatment of nonalcoholic fatty liver disease can improve the liver function and blood lipid levels, is worth the clinical promotion and application.
